scholarly journals Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Mycoses ◽  
2020 ◽  
Vol 63 (7) ◽  
pp. 653-682 ◽  
Author(s):  
Markus Ruhnke ◽  
Oliver A. Cornely ◽  
Martin Schmidt‐Hieber ◽  
Nael Alakel ◽  
Boris Boell ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Cancer Patients ◽  
Working Party ◽  
German Society ◽  
Fungal Diseases ◽  
Invasive Fungal Diseases

scholarly journals Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

2021 ◽  
Author(s):  
Annika Y. Classen ◽  
Larissa Henze ◽  
Marie von Lilienfeld-Toal ◽  
Georg Maschmeyer ◽  
Michael Sandherr ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Cancer Patients ◽  
Bacterial Infections ◽  
Medical Oncology ◽  
Working Party ◽  
German Society ◽  
Pneumocystis Jirovecii ◽  
Antibacterial Prophylaxis ◽  
Oncologic Patients ◽  
The Impact

AbstractHematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new research reshapes our understanding of the interactions between the human host and bacterial commensals, administration of antibacterial prophylaxis has become a matter of discussion. This guideline constitutes an update of the 2013 published guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). It gives an overview about current strategies for antibacterial prophylaxis in cancer patients while taking into account the impact of antibacterial prophylaxis on the human microbiome and resistance development. Current literature published from January 2012 to August 2020 was searched and evidence-based recommendations were developed by an expert panel. All recommendations were discussed and approved in a consensus conference of the AGIHO prior to publication. As a result, we present a comprehensive update and extension of our guideline for antibacterial and PcP prophylaxis in cancer patients.

scholarly journals Central venous catheter–related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

2020 ◽  
Vol 100 (1) ◽  
pp. 239-259
Author(s):  
Boris Böll ◽  
Enrico Schalk ◽  
Dieter Buchheidt ◽  
Justin Hasenkamp ◽  
Michael Kiehl ◽  
...  
Keyword(s):  
Central Venous Catheter ◽  
Infectious Diseases ◽  
Cancer Patients ◽  
Medical Oncology ◽  
Working Party ◽  
Venous Catheter ◽  
German Society ◽  
Central Venous ◽  
Literature Searches ◽  
Anti Cancer

AbstractCancer patients frequently require central venous catheters for therapy and parenteral nutrition and are at high risk of central venous catheter–related infections (CRIs). Moreover, CRIs prolong hospitalization, cause an excess in resource utilization and treatment cost, often delay anti-cancer treatment, and are associated with a significant increase in mortality in cancer patients. We therefore summoned a panel of experts by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and updated our previous guideline on CRIs in cancer patients. After conducting systematic literature searches on PubMed, Medline, and Cochrane databases, video- and meeting-based consensus discussions were held. In the presented guideline, we summarize recommendations on definition, diagnosis, management, and prevention of CRIs in cancer patients including the grading of strength of recommendations and the respective levels of evidence. This guideline supports clinicians and researchers alike in the evidence-based decision-making in the management of CRIs in cancer patients.

Sign in / Sign up

Export Citation Format

Share Document